ArticleInternational journal of general medicine2025
TRIM6 Promotes Cell Cycle and Growth by Modulating p53 Signaling Pathway in Lung Adenocarcinoma.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- UBE2W promotes pancreatic cancer progression through regulating K63-linked ubiquitination of p53.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Accumulated evidence suggested that tripartite motif-containing (TRIM) proteins have a pivotal role in cancer progression. The function of TRIM6 remains largely unknown in lung adenocarcinoma (LUAD). This study aimed to clarify the role of TRIM6 in the LUAD pathogenesis. Methods: The genes involved in TRIM were selected by differential gene expression analysis and Cox regression analysis. TRIM6 was identified and verified in LUAD specimens and in paired normal tissues using immunohistochemistry. A correlation analysis was conducted comparing the expression of TRIM6 and clinicopathologic features. The role of TRIM6 in vitro and in vivo was evaluated by cell proliferation assays, cell apoptosis, cell cycle and a tumor xenograft model. Finally, we investigated downstream proteins regulated by TRIM6 by Western blotting. Results: Among TRIM proteins, TRIM6 expression was significantly elevated in LUAD tissues. The prognosis analysis demonstrated that high expression of TRIM6 was associated with unfavorable survival, which was consistent with the findings of Cox regression analysis. Further correlation analysis concluded that high TRIM6 expression was also associated with TNM staging. TRIM6 knockdown suppressed proliferation, induced cell apoptosis and cell cycle arrest in the G2/M phase. Furthermore, the exact effect of TRIM6 on LUAD cells was examined using in vivo experiments. Mechanistically, TRIM6 enhanced the biological capacity of LUAD cells through the p53 signaling pathway. Conclusion: Our study identifies TRIM6 is a potential oncogene and a prognostic target through the regulation of p53 signaling pathway in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.